Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]W. Yang, J. Lu, J. Weng, W. Jia and China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 362(12), 1090-101 (2010)

  • [2]L. G. Mellbin, M. Anselmino and L. Ryden: Diabetes, prediabetes and cardiovascular risk. Eur J Cardiovasc Prev Rehabil 17 Suppl 1, S9-14 (2010)

  • [3]M. Lotfy, J. Adeghate, H. Kalasz, J. Singh and E. Adeghate: Chronic complications of diabetes mellitus: A mini review. Curr Diabetes Rev (2015)

  • [4]A. C. Tricco, N. M. Ivers, J. M. Grimshaw, D. Moher, L. Turner: Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 379(9833), 2252-61 (2012)

  • [5]M. Authors/Task Force, L. Ryden, P. J. Grant, S. D. Anker, C. Berne, F: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39), 3035-87 (2013)

  • [6]P. Libby, P. M. Ridker and G. K. Hansson: Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-25 (2011)

  • [7]H. Vidula, K. Liu, M. H. Criqui, M. Szklo, M. Allison, C. Sibley, P. Ouyang, R. P. Tracy, C. Chan and M. M. McDermott: Metabolic syndrome and incident peripheral artery disease - the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 243(1), 198-203 (2015)

  • [8]Y. H. Chen, S. J. Lin, F. Y. Lin, T. C. Wu, C. R. Tsao, P. H. Huang, P. L. Liu, Y. L. Chen and J. W. Chen: High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 56(6), 1559-68 (2007)

  • [9]V. K. Bajpai and S. T. Andreadis: Stem cell sources for vascular tissue engineering and regeneration. Tissue Eng Part B Rev 18(5), 405-25 (2012)

  • [10]J. M. Hill, G. Zalos, J. P. Halcox, W. H. Schenke, M. A. Waclawiw, A. A. Quyyumi and T. Finkel: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7), 593-600 (2003)

  • [11]H. Zheng, G. Fu, T. Dai and H. Huang: Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 50(3), 274-80(2007)

  • [12]S. Meng, J. T. Cao, B. Zhang, Q. Zhou, C. X. Shen and C. Q. Wang: Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 53(1), 64-72 (2012)

  • [13]M. Brownlee: Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813-20 (2001)

  • [14]M. Brownlee: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6), 1615-25 (2005)

  • [15]Y. Wang, X. Chen, W. Cao and Y. Shi: Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15(11), 1009-16 (2014)

  • [16]P. J. Grant: Diabetes mellitus as a prothrombotic condition. J Intern Med 262(2), 157-72 (2007)

  • [17]J. E. Fish, M. M. Santoro, S. U. Morton, S. Yu, R. F. Yeh, J. D. Wythe, K. N. Ivey, B. G. Bruneau, D. Y. Stainier and D. Srivastava: miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15(2), 272-84(2008)

  • [18]C. van Solingen, H. C. de Boer, R. Bijkerk, M. Monge, A. M. van Oeveren-Rietdijk, L. Seghers, M. R. de Vries, E. P. van der Veer, P. H. Quax, T. J. Rabelink and A. J. van Zonneveld: MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1 (+)/Lin (-) progenitor cells in ischaemia. Cardiovasc Res 92(3), 449-55 (2011)

  • [19]N. M. Kane, A. J. Thrasher, G. D. Angelini and C. Emanueli: Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells 32(5), 1059-66 (2014)

  • [20]B. Yan, J. Yao, J. Y. Liu, X. M. Li, X. Q. Wang, Y. J. Li, Z. F. Tao, Y. C. Song, Q. Chen and Q. Jiang: lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res 116(7), 1143-56 (2015)

  • [21]S. Meng, J. Cao, X. Zhang, Y. Fan, L. Fang, C. Wang, Z. Lv, D. Fu and Y. Li: Downregulation of microRNA-130a contributes to endothelial progenitor cell dysfunction in diabetic patients via its target Runx3. PLoS One 8(7), e68611 (2013)

  • [22]A. Schober, M. Nazari-Jahantigh and C. Weber: MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis. Nat Rev Cardiol 12(6), 361-74 (2015)

  • [23]H. W. Wang, T. S. Huang, H. H. Lo, P. H. Huang, C. C. Lin and S. M. Cheng: Deficiency of the microRNA-31-microRNA-720 pathway in the plasma and endothelial progenitor cells from patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 34(4), 857-69 (2014)

  • [24]Y. Lee, C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Radmark, S. Kim and V. N. Kim: The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-9 (2003)

  • [25]J. Han, Y. Lee, K. H. Yeom, J. W. Nam, I. Heo, J. K. Rhee, S. Y. Sohn, Y. Cho, B. T. Zhang and V. N. Kim: Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125(5), 887-901 (2006)

  • [26]K. H. Yeom, Y. Lee, J. Han, M. R. Suh and V. N. Kim: Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res 34(16), 4622-9 (2006)

  • [27]M. Ghildiyal and P. D. Zamore: Small silencing RNAs: an expanding universe. Nat Rev Genet 10(2), 94-108 (2009)

  • [28]J. Han, Y. Lee, K. H. Yeom, Y. K. Kim, H. Jin and V. N. Kim: The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 18(24), 3016-27 (2004)

  • [29]A. D. Redfern, S. M. Colley, D. J. Beveridge, N. Ikeda: RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci U S A 110(16), 6536-41 (2013)

  • [30]D. P. BartTel: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-97 (2004)

  • [31]J. Hausser and M. Zavolan: Identification and consequences of miRNA-target interactions--beyond repression of gene expression. Nat Rev Genet 15(9), 599-612 (2014)

  • [32]H. Seitz, M. Ghildiyal and P. D. Zamore: Argonaute loading improves the 5’ precision of both MicroRNAs and their miRNA strands in flies. Curr Biol 18(2), 147-51 (2008)

  • [33]X. Liu, B. Duan, Z. Cheng, X. Jia, L. Mao, H. Fu, Y. Che, L. Ou, L. Liu and D. Kong: SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell 2(10), 845-54 (2011)

  • [34]V. Ambros: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell, 113(6), 673-6 (2003)

  • [35]C. Beltrami, T. G. Angelini and C. Emanueli: Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol 89(Pt A), 42-50 (2015)

  • [36]W. J. Yang, D. D. Yang, S. Na, G. E. Sandusky, Q. Zhang and G. Zhao: Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 280(10), 9330-5 (2005)

  • [37]Y. Suarez, C. Fernandez-Hernando, J. S. Pober and W. C. Sessa: Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100(8), 1164-73 (2007)

  • [38]A. Zampetaki, P. Willeit, S. Burr, X. Yin, S. R. Langley, S. Kiechl, R. Klein, P. Rossing, N. Chaturvedi and M. Mayr: Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. Diabetes 65(1), 216-27(2016)

  • [39]X. Zhong, A. C. Chung, H. Y. Chen, Y. Dong, X. M. Meng, R. Li, W. Yang, F. F. Hou and H. Y. Lan: miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56(3), 663-74 (2013)

  • [40]S. Akhtar, P. Hartmann, E. Karshovska, F. A. Rinderknecht, P. Subramanian, F. Gremse, J. Grommes, M. Jacobs, F. Kiessling, C. Weber, S. Steffens and A. Schober: Endothelial Hypoxia-Inducible Factor-1alpha Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a. Hypertension 66(6), 1220-6 (2015)

  • [41]W. L. Jiang, Y. F. Zhang, Q. Q. Xia, J. Zhu, X. Yu, T. Fan and F. Wang: MicroRNA-19a regulates lipopolysaccharide-induced endothelial cell apoptosis through modulation of apoptosis signal-regulating kinase 1 expression. BMC Mol Biol 16, 11 (2015)

  • [42]A. D. McClelland, M. Herman-Edelstein, R. Komers, J. C. Jha, C. E. Winbanks, S. Hagiwara, P. Gregorevic, P. Kantharidis and M. E. Cooper: miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 129(12), 1237-49 (2015)

  • [43]H. Zhu and S. W. Leung: Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 58(5), 900-11 (2015)

  • [44]L. Zhang, S. He, S. Guo, W. Xie, R. Xin, H. Yu, F. Yang, J. Qiu, D. Zhang, S. Zhou and K. Zhang: Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1. J Diabetes Complications 28(3), 259-64 (2014)

  • [45]Q. Chen, F. Yang, M. Guo, G. Wen, C. Zhang, A. Luong le, J. Zhu, Q. Xiao and L. Zhang: miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration. J Mol Cell Cardiol 89(Pt A), 75-86 (2015)

  • [46]M. B. Backe, G. W. Novotny, D. P. Christensen, L. G. Grunnet and T. Mandrup-Poulsen: Altering beta-cell number through stable alteration of miR-21 and miR-34a expression. Islets 6(1), e27754 (2014)

  • [47]F. He, F. Peng, X. Xia, C. Zhao, Q. Luo, W. Guan, Z. Li, X. Yu and F. Huang: MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia 57(8), 1726-36 (2014)

  • [48]P. Agarwal, R. Srivastava, A. K. Srivastava, S. Ali and M. Datta: miR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochim Biophys Acta 1832(8), 1294-303 (2013)

  • [49]J. Xu, L. Li, H. F. Yun and Y. S. Han: MiR-138 promotes smooth muscle cells proliferation and migration in db/db mice through down-regulation of SIRT1. Biochem Biophys Res Commun 463(4), 1159-64 (2015)

  • [50]A. M. Khamaneh, M. R. Alipour, F. Sheikhzadeh Hesari and F. Ghadiri Soufi: A signature of microRNA-155 in the pathogenesis of diabetic complications. J Physiol Biochem 71(2), 301-9 (2015)

  • [51]Y. Huang, Y. Liu, L. Li, B. Su, L. Yang, W. Fan and F. Liu: Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury. BMC Nephrol 15, 142 (2014)

  • [52]Y. Zhang, H. Q. Xiao, Y. Wang, Z. S. Yang, L. J. Dai and Y. C. Xu: Differential expression and therapeutic efficacy of microRNA-346 in diabetic nephropathy mice. Exp Ther Med 10(1), 106-112 (2015)

  • [53]C. H. Liu, Y. Sun, J. Li, Y. Gong, K. T. Tian, L. P. Evans, P. C. Morss, T. W. Fredrick, N. J. Saba and J. Chen: Endothelial microRNA-150 is an intrinsic suppressor of pathologic ocular neovascularization. Proc Natl Acad Sci U S A 112(39), 12163-8 (2015)

  • [54]A. Caporali, M. Meloni, A. Nailor, T. Mitic, S. Shantikumar and C. Emanueli: p75 (NTR)-dependent activation of NF-kappaB regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. Nat Commun 6, 8024 (2015)

  • [55]H. Li, L. Chang, W. W. Du, S. Gupta, A. Khorshidi, M. Sefton and B. B. Yang: Anti-microRNA-378a enhances wound healing process by upregulating integrin beta-3 and vimentin. Mol Ther 22(10), 1839-50 (2014)

  • [56]A. Avogaro, M. Albiero, L. Menegazzo, S. de Kreutzenberg and G. P. Fadini: Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34 Suppl 2, S285-90 (2011)

  • [57]M. Kucia, B. Dawn, G. Hunt, Y. Guo, M. Wysoczynski and M. Z. Ratajczak: Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 95(12), 1191-9 (2004)

  • [58]G. P. Fadini: A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 57(1), 4-15 (2014)

  • [59]X. Zhao, D. Qian, N. Wu, Y. Yin, J. Chen, B. Cui and L. Huang: The spleen recruits endothelial progenitor cell via SDF-1/CXCR4 axis in mice. J Recept Signal Transduct Res 30(4), 246-54 (2010)

  • [60]Y. Wu, J. E. Ip, J. Huang, L. Zhang, K. Matsushita, C. C. Liew, R. E. Pratt and V. J. Dzau: Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res 99(3), 315-22 (2006)

  • [61]H. Jin, A. Aiyer, J. Su, P. Borgstrom, D. Stupack, M. Friedlander and J. Varner: A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 116(3), 652-62 (2006)

  • [62]M. Cheng, K. Huang, J. Zhou, D. Yan, Y. L. Tang, T. C. Zhao, R. J. Miller, R. Kishore, D. W. Losordo and G. Qin: A critical role of Src family kinase in SDF-1/CXCR4-mediated bone-marrow progenitor cell recruitment to the ischemic heart. J Mol Cell Cardiol 81, 49-53 (2015)

  • [63]A. R. Chade, X. Y. Zhu, J. D. Krier, K. L. Jordan, S. C. Textor, J. P. Grande, A. Lerman and L. O. Lerman: Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells 28(6), 1039-47 (2010)

  • [64]M. I. Saad, T. M. Abdelkhalek, M. M. Saleh, M. A. Kamel, M. Youssef, S. H. Tawfik and H. Dominguez: Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells. Endocrine 50(3), 537-67 (2015)

  • [65]N. Garcia de la Torre, R. Fernandez-Durango, R. Gomez and A. L. Calle-Pascual: Expression of Angiogenic MicroRNAs in Endothelial Progenitor Cells From Type 1 Diabetic Patients With and Without Diabetic Retinopathy. Invest Ophthalmol Vis Sci 56(6), 4090-8 (2015)

  • [66]T. Y. Chang, T. S. Huang, H. W. Wang, S. J. Chang and C. C. Cheng: miRNome traits analysis on endothelial lineage cells discloses biomarker potential circulating microRNAs which affect progenitor activities. BMC Genomics 15, 802 (2014)

  • [67]Q. Zhang, I. Kandic and M. J. Kutryk: Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem Biophys Res Commun 405(1), 42-6 (2011)

  • [68]K. Zuo, M. Li, X. Zhang, C. Lu, S. Wang, K. Zhi and B. He: MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGFbeta signaling pathway via downregulation of WWP1. Int J Clin Exp Pathol 8(1), 414-22 (2015)

  • [69]Y. Zheng and Z. Xu: MicroRNA-22 induces endothelial progenitor cell senescence by targeting AKT3. Cell Physiol Biochem 34(5), 1547-55 (2014)

  • [70]M. Ye, D. Li, J. Yang, J. Xie, F. Yu and Z. Lv: MicroRNA-130a Targets MAP3K12 to Modulate Diabetic Endothelial Progenitor Cell Function. Cell Physiol Biochem 36(2), 712-26 (2015)

  • [71]J. Zhang, Z. Zhang, D. Y. Zhang, J. Zhu, T. Zhang and C. Wang: microRNA 126 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PIK3R2-PI3K/Akt signalling pathway. PLoS One 8(12), e83294 (2013)

  • [72]W. Wang, C. Li, W. Li, L. Kong, A. Qian and X. Li: MiR-150 enhances the motility of EPCs in vitro and promotes EPCs homing and thrombus resolving in vivo. Thromb Res 133(4), 590-8 (2014)

  • [73]C. M. Su, C. J. Hsu, C. H. Tsai, C. Y. Huang, S. W. Wang and C. H. Tang: Resistin Promotes Angiogenesis in Endothelial Progenitor Cells Through Inhibition of MicroRNA206: Potential Implications for Rheumatoid Arthritis. Stem Cells 33(7), 2243-55 (2015)

  • [74]E. P. Chiang, S. C. Chiu, M. H. Pai, Y. C. Wang and F. Y. Tang: Organosulfur garlic compounds induce neovasculogenesis in human endothelial progenitor cells through a modulation of MicroRNA 221 and the PI3-K/Akt signaling pathways. J Agric Food Chem 61(20), 4839-49 (2013)

  • [75]K. A. Bano and A. Batool: Metabolic syndrome, cardiovascular disease and type-2 diabetes. J Pak Med Assoc 57(10), 511-5 (2007)

  • [76]V. Randriamboavonjy, J. Isaak, A. Elgheznawy, F. Pistrosch, T. Fromel, X. Yin, K. Badenhoop, H. Heide, M. Mayr and I. Fleming: Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. Blood 120(2), 415-23 (2012)

  • [77]A. Alban, S. O. David, L. Bjorkesten, C. Andersson, E. Sloge, S. Lewis and I. Currie: A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3(1), 36-44 (2003)

  • [78]V. Randriamboavonjy, J. Schrader, R. Busse and I. Fleming: Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med 199(3), 347-56 (2004)

  • [79]C. Stratz, T. G. Nuhrenberg, H. Binder, C. M. Valina, D. Trenk, W. Hochholzer, F. J. Neumann and B. L. Fiebich: Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA. Thromb Haemost 107(4), 634-41 (2012)

  • [80]A. Elgheznawy, L. Shi, J. Hu, I. Wittig, H. Laban, J. Pircher, A. Mann, P. Provost, V. Randriamboavonjy and I. Fleming: Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 117(2), 157-65 (2015)

  • [81]G. Rahimi, N. Jafari, M. Khodabakhsh, Z. Shirzad and H. P. Dogaheh: Upregulation of microRNA processing enzymes Drosha and Dicer in gestational diabetes mellitus. Gynecol Endocrinol 31(2), 156-9 (2015)

  • [82]A. Zampetaki, S. Kiechl, I. Drozdov, P. Willeit, U. Mayr, M. Prokopi and M. Mayr: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107(6), 810-7 (2010)

  • [83]D. S. Karolina, A. Armugam, S. Tavintharan, M. T. Wong and K. Jeyaseelan: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 6(8), e22839 (2011)

  • [84]X. Duan, Q. Zhan, B. Song, S. Zeng, J. Zhou, Y. Long and J. Xia: Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications 28(5), 705-10 (2014)

  • [8]S. Yang, J. Zhao, Y. Chen and M. Lei: Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients. Cardiovasc Toxicol (2015)

  • [86]Y. Zhang, Q. Guan and X. Jin: Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia. Exp Ther Med 9(6), 2257-2262 (2015)

  • [87]C. Stratz, T. Nuhrenberg, B. L. Fiebich and F. J. Neumann: Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients. Thromb Haemost 111(5), 902-11 (2014)

  • [88]A. Zampetaki and M. Mayr: Sweet dicer: impairment of micro-RNA processing by diabetes. Circ Res 117(2), 116-8 (2015)

  • [89]M. Verdoia, P. Pergolini, M. Nardin, R. Rolla, L. Barbieri, A. Schaffer and G. De Luca: Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. J Thromb Thrombolysis (2016)

  • [90]E. Yeom, H. Byeon and S. J. Lee: Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats. Sci Rep 621913 (2016)

  • [91]H. C. de Boer, C. van Solingen, J. Prins, J. M. Duijs, M. V. Huisman, T. J. Rabelink and A. J. van Zonneveld: Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 34(44), 3451-7 (2013)

  • [92]R. Shi, L. Ge, X. Zhou, W. J. Ji, R. Y. Lu, Y. Y. Zhang, S. Zeng, X. Liu, J. H. Zhao, W. C. Zhang, T. M. Jiang and Y. M. Li: Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res 131(6), 508-13 (2013)

  • [93]P. Willeit, A. Zampetaki, K. Dudek, D. Kaudewitz, A. King, N. S. Kirkby, R. Crosby-Nwaobi, M. Prokopi, I. Drozdov, S. R. Langley, S. Sivaprasad, H. S. Markus, J. A. Mitchell, T. D. Warner, S. Kiechl and M. Mayr: Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 112(4), 595-600 (2013)

  • [94]M. Luo, R. Li, X. Deng, M. Ren, N. Chen, M. Zeng, K. Yan, J. Xia, F. Liu, W. Ma, Y. Yang, Q. Wan and J. Wu: Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes. Acta Diabetol 52(5), 943-9 (2015)

  • [95]C. Cowan, C. K. Muraleedharan, J. J. O’Donnell, 3rd, P. K. Singh, H. Lum, A. Kumar and S. Xu: MicroRNA-146 inhibits thrombin-induced NF-kappaB activation and subsequent inflammatory responses in human retinal endothelial cells. Invest Ophthalmol Vis Sci 55(8), 4944-51 (2014)

  • [96]S. Fulzele, A. El-Sherbini, S. Ahmad, R. Sangani, S. Matragoon, A. El-Remessy, R. Radhakrishnan and G. I. Liou: MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes. Biomed Res Int 2015, 846501 (2015)

  • [97]R. L. Baldeon, K. Weigelt, H. de Wit, B. Ozcan, A. van Oudenaren, F. Sempertegui, E. Sijbrands, L. Grosse, W. Freire, H. A. Drexhage and P. J. Leenen: Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients. PLoS One 9(12), e115209 (2014)

  • [98]F. Olivieri, L. Spazzafumo, M. Bonafe, R. Recchioni, F. Prattichizzo, F. Marcheselli, L. Micolucci, E. Mensa, A. Giuliani, G. Santini, M. Gobbi, R. Lazzarini, M. Boemi, R. Testa, R. Antonicelli, A. D. Procopio and A. R. Bonfigli: MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 6(34), 35372-82 (2015)

  • [99]C. Cheng, M. Kobayashi, J. A. Martinez, H. Ng, J. J. Moser, X. Wang, V. Singh, M. J. Fritzler and D. W. Zochodne: Evidence for Epigenetic Regulation of Gene Expression and Function in Chronic Experimental Diabetic Neuropathy. J Neuropathol Exp Neurol 74(8), 804-17 (2015)

  • [100]J. Chen, R. Ning, A. Zacharek, C. Cui, X. Cui, T. Yan, P. Venkat, Y. Zhang and M. Chopp: MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice. Stem Cells 34(1), 102-13 (2016)

  • [101]N. Yousefzadeh, M. R. Alipour and F. G. Soufi: Deregulation of NF-small ka, CyrillicB-miR-146a negative feedback loop may be involved in the pathogenesis of diabetic neuropathy. J Physiol Biochem 71(1), 51-8 (2015)

  • [102]Y. Liu, G. Gao, C. Yang, K. Zhou, B. Shen, H. Liang and X. Jiang: Stability of miR-126 in Urine and Its Potential as a Biomarker for Renal Endothelial Injury with Diabetic Nephropathy. Int J Endocrinol 2014, 393109 (2014)

  • [103]S. Dangwal, B. Stratmann, C. Bang, J. M. Lorenzen, R. Kumarswamy, J. Fiedler, C. S. Falk, C. J. Scholz, T. Thum and D. Tschoepe: Impairment of Wound Healing in Patients With Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines. Arterioscler Thromb Vasc Biol 35(6), 1480-8 (2015)

  • [104]L. Bitterli, S. Afan, S. Buhler, S. DiSanto, M. Zwahlen, K. Schmidlin, Z. Yang, I. Baumgartner, N. Diehm and C. Kalka: Endothelial progenitor cells as a biological marker of peripheral artery disease. Vasc Med 21(1), 3-11 (2016)

  • [105]K. Riches, A. R. Alshanwani, P. Warburton, D. J. O’Regan, S. G. Ball, I. C. Wood, N. A. Turner and K. E. Porter: Elevated expression levels of miR-143/5 in saphenous vein smooth muscle cells from patients with Type 2 diabetes drive persistent changes in phenotype and function. J Mol Cell Cardiol 74, 240-50 (2014)

  • [106]A. D. Bhatwadekar, Y. Yan, V. Stepps, S. Hazra, M. Korah, S. Bartelmez, B. Chaqour and M. B. Grant: miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian Genes Involved in Progenitor Differentiation. Diabetes 64(12), 4226-37 (2015)

  • [107]J. Y. Wang, Y. B. Gao, N. Zhang, D. W. Zou, P. Wang, Z. Y. Zhu, J. Y. Li, S. N. Zhou, S. C. Wang, Y. Y. Wang and J. K. Yang: miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 392(1-2), 163-72 (2014)

  • [108]S. Xie, N. Xie, Y. Li, P. Wang, C. Zhang, Q. Li and C. Lv: Upregulation of TRB2 induced by miR-98 in the early lesions of large artery of type-2 diabetic rat. Mol Cell Biochem 361(1-2), 305-14 (2012)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review
MicroRNAs in control of gene regulatory programs in diabetic vasculopathy
Chongzhe Pei 1, Xiaoping Zhang 2, Meng Shu 1,*, Yigang Li 1
Affiliations
Article Info

1 Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Kongjiang Road 1665, Yangpu Distribution 200092, Shanghai, China

2 Institution of Interventional and Vascular, Tongji University School of Medicine, Middle Yanchang Road 301, Zhabei Distribution 200072, Shanghai, China

Abstract

Diabetes is generally associated with vasculopathy, which contains both microvascular and macrovascular complications, associated with high morbidity and mortality. Currently, despite interventional therapy, the overall prognosis for patients with diabetic vasculopathy remains unsatisfactory. Angiogenesis and vascular injury and repair are associated with a variety of cells. However, the molecular mechanisms of the cells that are involved in pathogenesis of diabetic vasculopathy remain largely unknown. As novel molecules, microRNAs (miRs) take part in regulating protein-coding gene expression at the post-transcriptional level, and contribute to the pathogenesis of various types of chronic metabolism disease, especially diabetic vasculopathy. This allows miRs to have a direct function in regulation of various cellular events. Additionally, circulating miRs have been proposed as biomarkers for a wide range of cardiovascular diseases. This review elucidates miR-mediated regulatory mechanisms in diabetic vasculopathy. Furthermore, we discuss the current understanding of miRs in diabetic vasculopathy. Finally, we summarize the development of novel diagnostic and therapeutic strategies for diabetic vasculopathy related to miRs.

Keywords

  • Diabetic Vasculopathy
  • MicroRNAs
  • Signaling Pathway
  • Review

References